ColinDWeekesMD

Clinical Trials

• Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 15

  Completed

  Phase 1

• PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14

  Completed

  Phase 2

• Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05

  Completed

  Phase 2

• Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2013 Nov 01

  Completed

  Phase 1

• Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Start of enrollment: 2016 Dec 30

  Active, not recruiting

  Phase 2

• A Study of LY2510924 and Durvalumab in Participants With Solid Tumors Start of enrollment: 2016 Sep 01

  Terminated

  Phase 1

• A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Start of enrollment: 2017 Jan 12

  Completed

  Phase 2

• A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors Start of enrollment: 2021 Jun 15

  Recruiting

  Phase 1, Phase 2

• SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells Start of enrollment: 2021 Jan 13

  Recruiting

  Phase 1

  Roles: Contact, Principal Investigator

• FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer Start of enrollment: 2022 Mar 21

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator, Sponsor-Investigator

• FOLFIRINOX + NIS793 in Pancreatic Cancer Start of enrollment: 2022 Aug 09

  Recruiting

  Phase 1

  Roles: Principal Investigator, Sponsor-Investigator, Contact

• A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Start of enrollment: 2021 Oct 04

  Active, not recruiting

  Phase 1

  Roles: Contact, Principal Investigator

• A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors Start of enrollment: 2023 Apr 14

  Recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator, Contact

• Join now to see all